Transitional cell carcinoma epidemiology and demographics

Jump to navigation Jump to search

Transitional cell carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Transitional cell carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Cystoscopy and Bladder Biopsy

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Transitional cell carcinoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Transitional cell carcinoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Transitional cell carcinoma epidemiology and demographics

CDC on Transitional cell carcinoma epidemiology and demographics

Transitional cell carcinoma epidemiology and demographics in the news

Blogs on Transitional cell carcinoma epidemiology and demographics

Directions to Hospitals Treating Transitional cell carcinoma

Risk calculators and risk factors for Transitional cell carcinoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Epidemiology and Demographics

  • Transitional cell carcinoma of the renal pelvis, accounts for only 7% of all kidney tumors.[1]
  • Transitional cell cancer of the ureter, accounts for only 1 of every 25 upper tract tumors.
  • They are curable in more than 90% of patients if they are superficial and confined to the renal pelvis or ureter.
  • Patients with deeply invasive tumors that are still confined to the renal pelvis or ureter have a 10% to 15% likelihood of cure.
  • Patients with tumors with penetration through the urothelial wall or with distant metastases usually cannot be cured with currently available forms of treatment.

Age

Transitional cell carcinoma is typically a tumor of older patients, with the average age of presentation being 65, and the majority of patients being over the age of 60.

Gender

There is a strong male predilection (M:F = 4:1), at least in part due to many tumors (especially historically) having been due to industrial exposure.

References

  1. Transitional cell cancer. National cancer institute. http://www.cancer.gov/types/kidney/hp/transitional-cell-treatment-pdq#section/_1

Template:WH Template:WS